Who is sponsoring NCT00443170?

NCT00443170 is sponsored by GlaxoSmithKline.

What condition does NCT00443170 study?

NCT00443170 studies Healthy Subjects, Anaemia.

What drugs are being tested in NCT00443170?

Interventions: GSK626616, placebo, midazolam, omeprazole, caffeine, flurbiprofen, rosiglitazone.

What is the status of NCT00443170?

NCT00443170 is currently COMPLETED.

Last reviewed 2012-03-15 · How we verify

A Randomized, Blinded, Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of Single and Repeat Dose Escalation of the Oral YAK3/DYRK3 Inhibitor GSK626616AC in Healthy Subjects

NCT00443170 Phase 1 COMPLETED

This is a first time in human study to investigate the safety of GSK626616AC given as oral single and repeat doses in healthy subjects. An additional group of subjects will be assessed to determine the effect of several drugs given at the same time as GSK626616.

Details

Lead sponsor	GlaxoSmithKline
Phase	Phase 1
Status	COMPLETED
Enrolment	90
Start date	2006-11

Conditions

Healthy Subjects
Anaemia

Interventions

GSK626616, placebo, midazolam
omeprazole, caffeine, flurbiprofen, rosiglitazone

Primary outcomes

adverse events at end of each cohort — end of each cohort
hematology/chemistry/urinalysis at end of each cohort — end of each cohort
physical examination at end of each cohort — end of each cohort
vital signs and electrocardiogram (ECG) at end of each cohort — end of each cohort

Countries

Australia